KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) EBT Margin (2016 - 2025)

TherapeuticsMD's EBT Margin history spans 16 years, with the latest figure at 64.95% for Q4 2025.

  • For Q4 2025, EBT Margin fell 7739.0% year-over-year to 64.95%; the TTM value through Dec 2025 reached 21.61%, up 11144.0%, while the annual FY2025 figure was 21.61%, 11144.0% up from the prior year.
  • EBT Margin reached 64.95% in Q4 2025 per TXMD's latest filing, down from 6.38% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 268.5% in Q4 2021 to a low of 4273.85% in Q2 2022.
  • Average EBT Margin over 5 years is 815.43%, with a median of 192.45% recorded in 2021.
  • Peak YoY movement for EBT Margin: tumbled -408842bps in 2022, then soared 372145bps in 2023.
  • A 5-year view of EBT Margin shows it stood at 268.5% in 2021, then crashed by -74bps to 70.67% in 2022, then plummeted by -547bps to 315.54% in 2023, then surged by 104bps to 12.44% in 2024, then crashed by -622bps to 64.95% in 2025.
  • Per Business Quant, the three most recent readings for TXMD's EBT Margin are 64.95% (Q4 2025), 6.38% (Q3 2025), and 57.25% (Q2 2025).